Genetic testing can lead to a diagnosis in around three quarters of children with short stature from consanguineous families, suggests a study of Turkish patients.
Most transgender adolescents treated with a gonadotropin-releasing hormone (GnRH) agonist plus oestradiol or testosterone reach an adult height that is within 2 standard deviations of that expected for their sex assigned at birth, research shows.
Vosoritide may be given to children with achondroplasia aged under 60 months after phase 2 trial findings point to a tolerable adverse event profile and an increase in height Z score compared with placebo.
Exome sequencing and chromosomal microarray analysis are useful tools for the identification of genetic causes underlying short stature, indicate the results of a systematic review and meta-analysis.
Gonadotropin-releasing hormone agonist therapy in children with congenital adrenal hyperplasia does not compromise bone mineral density, US researchers say.
The Insights into MAnaging Growth for Endocrine nurses (IMAGE) March 2024 Meeting, organised by Springer Healthcare IME, provides high-quality, practical clinical training for nurses involved in paediatric endocrinology practice.
Adolescents with a history of idiopathic central precocious puberty may be at increased risk of polycystic ovary syndrome, researchers report.
Two-year findings from the REAL4 trial support a switch from daily growth hormone to a weekly dose of the long-acting derivative somapacitan for prepubertal children with GH deficiency.
Multifocal disease does not predict a poor outcome in children and adolescents with papillary thyroid cancer, suggest study findings from the Memorial Sloan Kettering Cancer Center in New York, USA.
Research shows that growth hormone stimulation testing failure is more common in children with short stature or impaired linear growth who also have a diagnosis of attention deficit hyperactivity disorder.
